Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 1, 2014, Pages 73-79

  Delgado, Julio ^a   Ghita, Gabriela ^a   Baumann, Tycho ^a   Santacruz, Rodrigo ^a   Dlouhy, Ivan ^a   Aymerich, Marta ^b   Rozman, Maria ^b   Creus, Natalia ^b   Pereira, Arturo ^b   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Anti CD20; CLL; OS; Purine analogues; Treatment

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OVERALL SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ANTI-CD20; CLL; OS; PURINE ANALOGUES; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PURINES; YOUNG ADULT;

EID: 84892794971     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.08.003     Document Type: Article

References (35)

1. J.G. Gribben, and S. O'Brien Update on therapy of chronic lymphocytic leukemia J Clin Oncol 29 2011 544 550
2. M.J. Keating, S. O'Brien, and M. Albitar et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
3. C.S. Tam, S. O'Brien, and W. Wierda et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 2008 975 980
4. W. Wierda, S. O'Brien, and S. Wen et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078
5. M. Hallek, K. Fischer, and G. Fingerle-Rowson et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
6. K. Fischer, J. Bahlo, and A.M. Fink et al. Extended follow-up of the CLL8 protocol, a randomized phase III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen (abstract) Blood 120 2012 345
7. T. Robak, A. Dmoszynska, and P. Solal-Celigny et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
8. F. Bosch, P. Abrisqueta, and N. Villamor et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia J Clin Oncol 27 2009 4578 4584
9. S. Faderl, W. Wierda, and S. O'Brien et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 years Leuk Res 34 2010 284 288
10. P. Hillmen, D.R. Cohen, and K. Cocks et al. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia Br J Haematol 152 2011 570 578
11. C.S. Tam, and M.J. Keating Chemoimmunotherapy of chronic lymphocytic leukemia Nat Rev Clin Oncol 7 2010 521 532
12. J.A. Woyach, A.S. Ruppert, and N.A. Heerema et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 J Clin Oncol 29 2011 1349 1355
13. M.D. Danese, R.I. Griffiths, and M. Gleeson et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia Blood 117 2011 3505 3513
14. F. Bosch, A. Ferrer, and A. Lopez-Guillermo et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia Br J Haematol 119 2002 976 984
15. F. Bosch, A. Ferrer, and N. Villamor et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication Clin Cancer Res 14 2008 155 161
16. M. Hallek, B.D. Cheson, and D. Catovsky et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456
17. B.D. Cheson, J.M. Bennett, and M. Grever et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
18. B.D. Cheson, J.M. Bennett, and K.R. Rai et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group Am J Hematol 29 1988 152 163
19. R.T. Silver, A. Sawitsky, and K. Rai et al. Guidelines for protocol studies in chronic lymphocytic leukemia Am J Hematol 4 1978 343 358
20. M. Crespo, F. Bosch, and N. Villamor et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl J Med 348 2003 1764 1775
21. E. von Elm, D.G. Altman, and M. Egger et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet 370 2007 1453 1457
22. S.Y. Kristinsson, P.W. Dickman, and W.H. Wilson et al. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden Haematologica 94 2009 1259 1265
23. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), based on November 2011 SEER data submission, posted to the SEER web site, 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed: March 10, 2013.
24. D. Catovsky, S. Richards, and E. Matutes et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
25. W.U. Knauf, T. Lissichkov, and A. Aldaoud et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 2009 4378 4384
26. K.R. Rai, B.L. Peterson, and F.R. Appelbaum et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
27. B.F. Eichhorst, R. Busch, and S. Stilgenbauer et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 2009 3382 3391
28. D. Oscier, R. Wade, and Z. Davis et al. Prognostic factors identify three risk groups in the LRF CLL4 trial, independent of treatment allocation Haematologica 95 2010 1705 1712
29. M.R. Grever, D.M. Lucas, and G.W. Dewald et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 J Clin Oncol 25 2007 799 804
30. J.A. Woyach, A.S. Ruppert, and K. Rai et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of a sequential Cancer and Leukemia Group B studies J Clin Oncol 31 2013 440 447
31. L. Mauri Why we still need randomized trials to compare effectiveness N Engl J Med 366 2012 1538 1540
32. H.G. Van Spall, A. Toren, and A. Kiss et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review JAMA 297 2007 1233 1240
33. G.A. Abel The real world: CLL Blood 117 2011 3481 3482
34. CLL Trialists' Collaborative Group Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials J Natl Cancer Inst 91 1999 861 868
35. CLL Trialists' Collaborative Group Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials Haematologica 97 2012 428 436